Panel Overwhelmingly Supports Boehringer COPD Drug Striverdi

January 30, 2013
An FDA advisory panel voted 15–1 with one abstention that Boehringer Ingelheim’s (BI) long-acting inhaler Striverdi Respimat has an acceptable risk-benefit profile as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The Pulmonary-Allergy Drugs Advisory Committee (PADAC) gave two more identical votes Wednesday on the drug’s efficacy profile and safety profile.
Drug Industry Daily